A Long-Term Study of Rovalpituzumab Tesirine

NCT03543358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: rovalpituzumab tesirine
DRUG: rovalpituzumab tesirine

Sponsor

AbbVie